Literature DB >> 16051643

Conditional expression of the mutant Ki-rasG12C allele results in formation of benign lung adenomas: development of a novel mouse lung tumor model.

Heather S Floyd1, Charles L Farnsworth, Nancy D Kock, Melissa C Mizesko, Joy L Little, Stephanie T Dance, Jeff Everitt, Jay Tichelaar, Jeffrey A Whitsett, Mark Steven Miller.   

Abstract

To determine the effects of expression of mutant Ki-ras on lung tumorigenesis, we developed a bitransgenic mouse model that expresses the human Ki-ras(G12C) allele in alveolar type II and/or Clara cells in a tetracycline-inducible, lung-specific manner. Expression of Ki-ras(G12C) caused multiple, small lung tumors over a 12-month time period. Although tumor multiplicity increased upon continued Ki-ras expression, most lung lesions were hyperplasias or well-differentiated adenomas. This is in contrast to the more severe phenotypes observed in other transgenic mouse models in which different mutant Ki-ras alleles were expressed in the lung. Expression of Ki-ras(G12C) was associated with a 2-fold increase in the activation of the Ras and Ral signaling pathways and increased phosphorylation of Ras downstream effectors, including Erk, p90 ribosomal S6 kinase, ribosomal S6 protein, p38 and MAPKAPK-2. In contrast, expression of the transgene had no effect on the activation of the JNK and Akt signaling pathways. Withdrawal of doxycycline for 1 month resulted in almost a complete absence of proliferative pulmonary lesions, suggesting tumor regression in the absence of Ki-ras expression. Mutant Ki-ras(G12C) expression was sufficient for initial lung tumor transformation, required for maintenance of tumor phenotype, and induced transformation of lung epithelial cells by the activation of multiple effector pathways. These results describe a novel mouse lung tumor model demonstrating benign tumor development in the absence of tumor progression, which will provide a new tool for understanding the early stages of lung tumor pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16051643      PMCID: PMC1351110          DOI: 10.1093/carcin/bgi190

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  64 in total

1.  Constitutive JNK activation in NIH 3T3 fibroblasts induces a partially transformed phenotype.

Authors:  Ulrike E E Rennefahrt; Bertram Illert; Eugen Kerkhoff; Jakob Troppmair; Ulf R Rapp
Journal:  J Biol Chem       Date:  2002-05-30       Impact factor: 5.157

2.  The search for physiological substrates of MAP and SAP kinases in mammalian cells.

Authors:  P Cohen
Journal:  Trends Cell Biol       Date:  1997-09       Impact factor: 20.808

3.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Authors:  E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

4.  Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA.

Authors:  T Mukhopadhyay; M Tainsky; A C Cavender; J A Roth
Journal:  Cancer Res       Date:  1991-03-15       Impact factor: 12.701

Review 5.  Developments in quantitative PCR.

Authors:  C Orlando; P Pinzani; M Pazzagli
Journal:  Clin Chem Lab Med       Date:  1998-05       Impact factor: 3.694

6.  Strain-dependent lung tumor formation in mice transplacentally exposed to 3-methylcholanthrene and post-natally exposed to butylated hydroxytoluene.

Authors:  K M Gressani; S Leone-Kabler; M G O'Sullivan; L D Case; A M Malkinson; M S Miller
Journal:  Carcinogenesis       Date:  1999-11       Impact factor: 4.944

7.  K-ras is essential for the development of the mouse embryo.

Authors:  K Koera; K Nakamura; K Nakao; J Miyoshi; K Toyoshima; T Hatta; H Otani; A Aiba; M Katsuki
Journal:  Oncogene       Date:  1997-09-04       Impact factor: 9.867

8.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

9.  Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

Authors:  M Serrano; A W Lin; M E McCurrach; D Beach; S W Lowe
Journal:  Cell       Date:  1997-03-07       Impact factor: 41.582

10.  beta-Catenin is required for specification of proximal/distal cell fate during lung morphogenesis.

Authors:  Michael L Mucenski; Susan E Wert; Jennifer M Nation; David E Loudy; Joerg Huelsken; Walter Birchmeier; Edward E Morrisey; Jeffrey A Whitsett
Journal:  J Biol Chem       Date:  2003-07-28       Impact factor: 5.157

View more
  24 in total

1.  MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms.

Authors:  Dean W Felsher
Journal:  Genes Cancer       Date:  2010-06

Review 2.  Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine.

Authors:  Jacqueline V Aredo; Sukhmani K Padda
Journal:  Curr Treat Options Oncol       Date:  2018-06-27

3.  Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.

Authors:  Nathan T Ihle; Lauren A Byers; Edward S Kim; Pierre Saintigny; J Jack Lee; George R Blumenschein; Anne Tsao; Suyu Liu; Jill E Larsen; Jing Wang; Lixia Diao; Kevin R Coombes; Lu Chen; Shuxing Zhang; Mena F Abdelmelek; Ximing Tang; Vassiliki Papadimitrakopoulou; John D Minna; Scott M Lippman; Waun K Hong; Roy S Herbst; Ignacio I Wistuba; John V Heymach; Garth Powis
Journal:  J Natl Cancer Inst       Date:  2012-01-13       Impact factor: 13.506

4.  Conditional expression of oncogenic C-RAF in mouse pulmonary epithelial cells reveals differential tumorigenesis and induction of autophagy leading to tumor regression.

Authors:  Fatih Ceteci; Jiajia Xu; Semra Ceteci; Emanuele Zanucco; Chitra Thakur; Ulf R Rapp
Journal:  Neoplasia       Date:  2011-11       Impact factor: 5.715

5.  Effects of mutant human Ki-ras(G12C) gene dosage on murine lung tumorigenesis and signaling to its downstream effectors.

Authors:  Stephanie T Dance-Barnes; Nancy D Kock; Heather S Floyd; Joseph E Moore; Libyadda J Mosley; Ralph B D'Agostino; Mark J Pettenati; Mark Steven Miller
Journal:  Toxicol Appl Pharmacol       Date:  2008-04-27       Impact factor: 4.219

6.  Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M.

Authors:  Shigeru Kawabata; José R Mercado-Matos; M Christine Hollander; Danielle Donahue; Willie Wilson; Lucia Regales; Mohit Butaney; William Pao; Kwok-Kin Wong; Pasi A Jänne; Phillip A Dennis
Journal:  Cell Rep       Date:  2014-06-12       Impact factor: 9.423

7.  Epistatic interactions govern chemically-induced lung tumor susceptibility and Kras mutation site in murine C57BL/6J-ChrA/J chromosome substitution strains.

Authors:  Lori D Dwyer-Nield; Jay McQuillan; Annie Hill-Baskin; Richard A Radcliffe; Ming You; Joseph H Nadeau; Alvin M Malkinson
Journal:  Int J Cancer       Date:  2010-01-01       Impact factor: 7.396

8.  A technique for murine irradiation in a controlled gas environment.

Authors:  M C Walb; J E Moore; A Attia; K T Wheeler; M S Miller; M T Munley
Journal:  Biomed Sci Instrum       Date:  2012

Review 9.  Oncogene-induced senescence: an essential role for Runx.

Authors:  Anna Kilbey; Anne Terry; Ewan R Cameron; James C Neil
Journal:  Cell Cycle       Date:  2008-05-29       Impact factor: 4.534

10.  Lung tumor promotion by curcumin.

Authors:  Stephanie T Dance-Barnes; Nancy D Kock; Joseph E Moore; Elaine Y Lin; Libyadda J Mosley; Ralph B D'Agostino; Thomas P McCoy; Alan J Townsend; Mark Steven Miller
Journal:  Carcinogenesis       Date:  2009-04-09       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.